Armata Pharmaceuticals Revenue 2006-2021 | ARMP

Armata Pharmaceuticals revenue from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Armata Pharmaceuticals Annual Revenue
(Millions of US $)
2020 $1
2019 $
2018 $
2017 $0
2016 $0
2015 $0
2014 $0
2013 $0
2012 $1
2009 $12
2008 $9
2007 $10
2006 $10
2005 $7
Armata Pharmaceuticals Quarterly Revenue
(Millions of US $)
2021-06-30 $1
2021-03-31 $1
2020-12-31 $1
2020-09-30 $0
2020-06-30 $0
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $0
2015-09-30 $0
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $-0
2013-09-30 $-0
2013-06-30 $0
2013-03-31 $0
2012-12-31
2009-12-31 $3
2009-09-30 $4
2009-06-30 $3
2009-03-31 $2
2008-12-31 $2
2008-09-30 $2
2008-06-30 $2
2008-03-31 $2
2007-12-31 $3
2007-09-30 $2
2007-06-30 $3
2007-03-31 $2
2006-12-31 $4
2006-09-30 $2
2006-06-30 $1
2006-03-31 $2
2005-12-31 $2
2005-09-30 $1
2005-06-30 $1
2005-03-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.082B $0.001B
Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.972B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.985B 20.30
Biohaven Pharmaceutical Holding (BHVN) United States $8.378B 0.00
Emergent Biosolutions (EBS) United States $2.740B 6.61
Arcus Biosciences (RCUS) United States $2.509B 0.00
Myovant Sciences (MYOV) United Kingdom $1.869B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.763B 0.00
Zymeworks (ZYME) Canada $1.061B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.333B 0.00
Enzo Biochem (ENZ) United States $0.157B 15.43